<DOC>
	<DOCNO>NCT00005634</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness suberoylanilide hydroxamic acid treat patient advanced primary metastatic solid tumor respond previous therapy .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid Treating Patients With Advanced Solid Tumors That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose suberoylanilide hydroxamic acid ( SAHA ) patient refractory malignancy . II . Assess pharmacokinetic profile SAHA patient . III . Assess biologic effect SAHA normal tissue tumor cell patient . OUTLINE : This dose-escalation study . Patients receive suberoylanilide hydroxamic acid ( SAHA ) IV 2 hour day 1-3 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Accelerated Phase : One patient per dose level receives escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede patient experience grade 2 great toxicity ( hemoglobin anemia ) first course 2 different patient experience grade 2 toxicity ( hemoglobin anemia ) course treatment . Standard Phase : Cohorts 3-6 patient receive escalate dos SAHA MTD determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 45 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary metastatic malignancy refractory standard therapy curative therapy exist No progressive metastatic disease require palliative therapy within 4 week study Progressive disease Increase preexisting lesion image physical examination Patients sole progression criterion increase biochemical marker ( e.g. , carcinoembryonic antigen CA 153 ) increase symptom eligible Prostate cancer must either progressive metastatic disease image study rise PSA value Minimum 3 rise PSA value obtain least 1 week apart , 2 rise PSA value 1 month apart , least 25 % overall increase Serum testosterone less 50 ng/mL Must maintain castrate status No active CNS epidural tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.0 mg/dL AST great 37 U/L PT great 14 second Renal : Creatinine great 2.0 mg/dL Cardiovascular : No significant cardiac disease No New York Heart Association class III IV heart disease Pulmonary : No severe debilitate pulmonary disease Other : No infection require IV antibiotic treatment No severe medical problem would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : Recovered prior endocrine therapy Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy target lesion Surgery : Not specify Other : At least 4 week since prior investigational anticancer drug recover No concurrent ketoconazole patient prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>